Case Report: Prolonged Survival Following EGFRvIII CAR T Cell Treatment for Recurrent Glioblastoma

Autologous chimeric antigen receptor (CAR) T cells targeted to epidermal growth factor receptor variant III (CAR T-EGFRvIII) have been developed and administered experimentally to treat patients with IDH1 wildtype recurrent glioblastoma (rGBM) (NCT02209376). We report the case of a 59-year-old patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Durgin, Joseph S., Henderson, Fraser, Nasrallah, MacLean P., Mohan, Suyash, Wang, Sumei, Lacey, Simon F., Melenhorst, Jan Joseph, Desai, Arati S., Lee, John Y. K., Maus, Marcela V., June, Carl H., Brem, Steven, O’Connor, Roddy S., Binder, Zev, O’Rourke, Donald M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8138201/
https://www.ncbi.nlm.nih.gov/pubmed/34026647
http://dx.doi.org/10.3389/fonc.2021.669071

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8138201/
https://www.ncbi.nlm.nih.gov/pubmed/34026647
http://dx.doi.org/10.3389/fonc.2021.669071

Ejemplares similares